AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10091410
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: Peripheral blood stem cells (PBSC) collected after induction and consolidation chemotherapy, followed by ABSCT immediately thereafter.
Trial: 10091410
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: PBSC collected after consolidation alone, followed by intermediate dose cytarabine (Ara‐C 1 g/m2/12 h x3 days) and mitoxantrone (12 mg/m2/d x3 days) as early intensification before ABSCT.
Trial: 7844085
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of salbutamol plus beclomethasone
Trial: 624427
Drug: Low-dose cortisone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cortisone
Trial: 30587521
Drug: Linoleic acid
RxNorm normalized name: Linoleic acid
DrugBank: Linoleic acid (DB14104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linoleic acid solution
Trial: 30587521
Drug: Sweet (sucrose)
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sweet (sucrose) solution
Trial: 30587521
Drug: Salty (NaCl)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salty (NaCl) solution
Trial: 30587521
Drug: Five FFA
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five FFA solutions
Trial: 26771291
Drug: Citalopram (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (8 weeks treatment)
Trial: 22115379
Drug: Solution Focused
RxNorm normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution Focused Therapy (SFT)
Trial: 16892911
Drug: Vaccine efficacy
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine efficacy against infection and disease
Trial: 15572812
Drug: Terbutaline (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (250 mcg, 3 puffs)
Trial: 15572812
Drug: Salbutamol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (100 mcg, 3 puffs)
Trial: 29253068
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg/day for 1 year
Trial: 24955550
Drug: Saffron aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saffron aqueous extract (SAE) 30 mg daily
Trial: 24955550
Drug: Crocin 30
RxNorm normalized name: CROCIN
DrugBank: Crocin (DB11874)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crocin 30 mg daily
Trial: 15914936
Drug: β-blockers, angiotensin-converting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-blockers, angiotensin-converting enzyme inhibitors, aldosterone antagonists, and statins
Trial: 7888013
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 (600 mg)
Trial: 7888013
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 before normal saline infusion
Trial: 1943180
Drug: Herbomineral formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbomineral formulation (Articulin‐F)
Trial: 22395893
Drug: Subthreshold laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subthreshold laser treatment (STLT)
Trial: 22395893
Drug: Threshold laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Threshold laser treatment (TLT)
Trial: 12150481
Drug: Streptomycin 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptomycin 30 mg/kg
Trial: 12150481
Drug: Streptomycin 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptomycin 15 mg/kg
Trial: 12150481
Drug: Streptomycin 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptomycin 7.5 mg/kg
Trial: 12150481
Drug: Paromomycin 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paromomycin 7.5 mg/kg
Trial: 1330386
Drug: Lisinopril 10-20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 10-20 mg once daily
Trial: 2869615
Drug: Propranolol in
RxNorm normalized name: propranolol Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol in a daily dose of 180 to 240 mg
Trial: 29071875
Drug: Oral-appliance plus
RxNorm normalized name: Interceptor Plus Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-appliance plus tadalafil (10 mg daily for 3 months)
Trial: 29071875
Drug: Oral-appliance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral-appliance
Trial: 29071875
Drug: Tadalafil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (10 mg daily for 3 months)
Trial: 25772743
Drug: Next.Step e-therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Next.Step e-therapeutic platform accessed during 24 weeks in addition to standard treatment program
Trial: 22715808
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of DHA
Trial: 21521341
Drug: Oral DHEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral DHEA 50 mg/day
Trial: 16581113
Drug: Intralesional interferon-alpha
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional interferon-alpha 2b combined with oral vitamin E
Trial: 16581113
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin E alone
Trial: 12701068
Drug: Mixed meals
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed meals containing 15,000 retinol equivalents (RE) of vitamin A (as retinyl palmitate) with 40 g of fat (butter)
Trial: 12701068
Drug: Mixed meals
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed meals containing 15,000 retinol equivalents (RE) of vitamin A (as retinyl palmitate) with 40 g of fat (olive oil)
Trial: 12701068
Drug: Mixed meals
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed meals containing 15,000 retinol equivalents (RE) of vitamin A (as retinyl palmitate) with 40 g of fat (sunflower oil)
Trial: 7963281
Drug: Home-based program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based program with music listening stress reduction techniques at weekly home visits by a music therapist
Trial: 7963281
Drug: Self-administered program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered program with music listening stress reduction techniques and moderate therapist intervention (weekly telephone call)
Trial: 3297718
Drug: Ambroxol (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol (120 mg/day) for 40 days after chemotherapy course
Trial: 25556490
Drug: Fluvoxamine combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine combined with oxycodone prolonged-release tablets
Trial: 25556490
Drug: Oxycodone prolonged-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone prolonged-release tablets alone (Control)
Trial: 17884832
Drug: Fixed-dose paediatric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose paediatric granule co-formulation (10-20 kg body weight)
Trial: 17884832
Drug: Free-dose co-blister
RxNorm normalized name: Blister Armour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free-dose co-blister tablet formulation of artesunate-mefloquine (>20-40 kg body weight)
Trial: 3353893
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (3.2 g eicosapentaenoic acid and 2.2 g docosahexaenoic acid daily)
Trial: 31227535
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral probiotic combination of Lactobacillus rhamnosus, GG (LGG) and Bifidobacterium animalis subsp. lactis, BB‐12 (BB‐12)
Trial: 28463747
Drug: CBT-SP (Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT-SP (Cognitive Behaviour Therapy with Support Person)
Trial: 28463747
Drug: CBT-A (Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT-A (Cognitive Behaviour Therapy Alone)
Trial: 23015541
Drug: Caffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated coffee (65 mg)
Trial: 21464363
Drug: High alcohol
RxNorm normalized name: High alcohol lager
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High alcohol dose (0.8 g/kg)
Trial: 9457454
Drug: Topical tetracaine
RxNorm normalized name: tetracaine Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tetracaine 1%
Trial: 9457454
Drug: Topical bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical bupivacaine 0.75%
Trial: 2514474
Drug: Oxamniquine 20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxamniquine 20, 30 or 40 mg/kg
Trial: 2514474
Drug: Praziquantel 20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel 20, 30 or 40 mg/kg
Trial: 2514474
Drug: Praziquantel 30
RxNorm normalized name: praziquantel 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel 30 or 40 mg/kg
Trial: 2514474
Drug: Higher dosages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dosages of both drugs
Trial: 2514474
Drug: Population chemotherapy
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Population chemotherapy
Trial: 2514474
Drug: Lower treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower treatment schedules
Trial: 1055315
Drug: Clonidine alone
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine alone or in conjunction with diuretics and other hypertensive drugs
Trial: 24663814
Drug: Xylitol chewing
RxNorm normalized name: xylitol Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol chewing gum (6 g/day for 5 weeks)
Trial: 23158806
Drug: AG200-15 Agile
RxNorm normalized name: AGIL-FA
DrugBank: AGIL-FA (DB16973)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG200-15 Agile Patch (AP) under normal conditions
Trial: 23158806
Drug: AG200-15 Agile
RxNorm normalized name: AGIL-FA
DrugBank: AGIL-FA (DB16973)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG200-15 Agile Patch (AP) under cool water conditions
Trial: 23158806
Drug: AG200-15 Agile
RxNorm normalized name: AGIL-FA
DrugBank: AGIL-FA (DB16973)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG200-15 Agile Patch (AP) under all conditions
Trial: 11254838
Drug: Fluid challenge
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid challenge (2-L) in intraoperative patients
Trial: 7913934
Drug: Adjunctive antithyroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive antithyroid drugs (MMI and L-T4)
Trial: 7913934
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (RAI and adjunctive antithyroid drugs)
Trial: 2847600
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg nedocromil sodium
Trial: 8386917
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg nedocromil sodium
Trial: 2847600
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg nedocromil sodium
Trial: 30471715
Drug: rhIGF-1/rhIGFBP-3 (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF-1/rhIGFBP-3 (250 µg/kg/24 hours, continuous intravenous infusion from <24 hours of birth to postmenstrual age 296/7 weeks)
Trial: 22142523
Drug: Greater occipital
RxNorm normalized name: greater celandine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Greater occipital nerve block with steroid
Trial: 19737849
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor prescribed to be taken as needed for relief of epigastric pain
Trial: 16490093
Drug: Caudal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal morphine (30 microg.kg(‐1) in 1 ml.kg(‐1) saline)
Trial: 11345025
Drug: Ukrain (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ukrain (10 mg every second day, repeated 10 times) and vitamin C (5.4 g every second day, repeated 10 times)
Trial: 11345025
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (vitamin C (5.4 g every second day, repeated 10 times) and normal saline (10 ml))
Trial: 9192511
Drug: Intermittent cyclical
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent cyclical etidronate (400 mg/day for 14 days) followed by cyclical calcitriol therapy (0.25 microg twice daily)
Trial: 9192511
Drug: Calcitriol (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol (0.25 microg/day) in combination with 100 IU intranasal salmon calcitonin every other day
Trial: 3515920
Drug: Flurbiprofen (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (200 to 300 mg total daily dosage, four times daily)
Trial: 15231982
Drug: Once-Daily Dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-Daily Dosing (ODD) of aminoglycosides
Trial: 15231982
Drug: Multiple Daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple Daily Dosing (MDD) of aminoglycosides
Trial: 9578507
Drug: Daily s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily s.c. injections of 0.9 mg/m2 hGH
Trial: 7715582
Drug: Antioxidant treatment
RxNorm normalized name: OCTINOXATE 6 g in 100 g / AVOBENZONE 1.7 g in 100 g TOPICAL CREAM [Renewing Antioxidant Treatment SPF 6 GNLD International]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant treatment with selenium
Trial: 7715582
Drug: Scavenger treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scavenger treatment
Trial: 619607
Drug: Diphenylhydantoin (DPH)
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diphenylhydantoin (DPH) at a concentration of 20 microgram/ml
Trial: 619607
Drug: Control solution
RxNorm normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control solution of orange juice
Trial: 30701613
Drug: Extended-release naltrexone
RxNorm normalized name: bupropion / naltrexone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release naltrexone (380 mg intramuscularly injected every four weeks)
Trial: 30701613
Drug: Buprenorphine-naloxone (flexible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine-naloxone (flexible 4-16 mg sublingual doses daily)
Trial: 30701613
Drug: Switching from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching from buprenorphine-naloxone to extended-release naltrexone
Trial: 26471464
Drug: Bexident Post
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bexident Post (BP) gel, used three times daily after tooth extraction.
Trial: 26471464
Drug: Bicarbonate (BC)
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicarbonate (BC) oral rinse, used three times daily after tooth extraction.
Trial: 22733001
Drug: Wild blueberry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wild blueberry drink (25 g freeze-dried powder providing 375 mg of ACNs)
Trial: 19923636
Drug: Oral solutions
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solutions of doxylamine succinate and pyridoxine hydrochloride
Trial: 7549079
Drug: Aspirin, beta-blockers,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, beta-blockers, converting enzyme inhibitors
Trial: 7549079
Drug: Newer antithrombotic
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newer antithrombotic and antiplatelet agents (hirudin, glycoprotein IIb/IIIa receptor antagonists)
Trial: 6975823
Drug: Trimethoprim (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim (300 mg once a day for seven days)
Trial: 6975823
Drug: Co-trimoxazole (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (160 mg trimethoprim, 800 mg sulphamethoxazole, two tablets twice a day for seven days)
Trial: 31766743
Drug: l-Carnitine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-Carnitine administration (200 mg/kg/day)
Trial: 31766743
Drug: l-Carnitine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-Carnitine administration (50-100 mg/kg/day)
Trial: 31766743
Drug: l-Carnitine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-Carnitine administration
Trial: 31766743
Drug: l-Carnitine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-Carnitine administration in ASD associated with genetic disorders
Trial: 21546089
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg VEGF Trap‐Eye every 4 weeks
Trial: 21546089
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg VEGF Trap‐Eye every 4 weeks
Trial: 21546089
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg VEGF Trap‐Eye for 3 initial monthly doses and then every 8 weeks
Trial: 21546089
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg VEGF Trap‐Eye for 3 initial monthly doses and then on an as‐needed (PRN) basis
Trial: 17278206
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation and anti-H pylori therapy
Trial: 15083479
Drug: Bayesian, counterfactual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bayesian, counterfactual approach using data augmentation (DA) algorithm
Trial: 11597814
Drug: Hyperfractionated radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiotherapy (HFRT) - 59.4 Gy in 54 1.1-Gy twice daily fractions
Trial: 11597814
Drug: Conventionally fractionated
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventionally fractionated radiotherapy (CFRT) - 50.4 Gy in 28 1.8-Gy daily fractions
Trial: 9588436
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of donepezil hydrochloride
Trial: 9588436
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of donepezil hydrochloride
Trial: 7985937
Drug: Protocol A
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol A (standard therapy regimen)
Trial: 7985937
Drug: Protocol B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol B (standard therapy regimen plus plasmapheresis)
Trial: 7985937
Drug: Protocol C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol C (standard therapy regimen plus pulse methylprednisolone)
Trial: 2574553
Drug: terfenadine 60
RxNorm normalized name: terfenadine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terfenadine 60 mg every 12 hours
Trial: 2574553
Drug: terfenadine 120
RxNorm normalized name: terfenadine 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terfenadine 120 mg each day
Trial: 31312144
Drug: Oral Contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Contraceptives (30 μg ethinyl estradiol)
Trial: 31312144
Drug: Oral Contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Contraceptives (20 μg ethinyl estradiol)
Trial: 24171791
Drug: Intraocular irrigating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraocular irrigating solution
Trial: 16443353
Drug: Ciclesonide (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclesonide (80 or 160 microg daily)
Trial: 16443353
Drug: Fluticasone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone (100 microg twice daily)
Trial: 16443353
Drug: Ciclesonide (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclesonide (160 microg daily)
Trial: 12960650
Drug: Erythromycin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (1.5 mg/kg)
Trial: 1831005
Drug: Dermal pretreatment
RxNorm normalized name: Dermal-Soothe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermal pretreatment with 0.5% hydrocortisone cream
Trial: 1831005
Drug: Dermal pretreatment
RxNorm normalized name: Dermal-Soothe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermal pretreatment with magnesium-aluminum hydroxide suspension
Trial: 1831005
Drug: Transdermal patch
RxNorm normalized name: TRANSDERMAL PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal patch alone
Trial: 1831005
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (hydrocortisone, magnesium-aluminum hydroxide, patch alone)
Trial: 7049351
Drug: Ascorbic acid,
RxNorm normalized name: ASCORBIC ACID, (-)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascorbic acid, 3 g/day